ABOUT
Mapping the Boundaries of Failure
Drug discovery has a 90% failure rate. We're building the platform that tells you exactly where — and why — before you spend billions finding out.
THE PROBLEM
The Problem With Point Estimates
Every AI drug discovery platform today gives you a number. hERG: 0.3. Binding affinity: −8.2 kcal/mol. But none of them tell you how confident they are in that number.
A medicinal chemist at a biotech spends months and millions of dollars synthesizing compounds based on these point estimates — only to discover in the lab that the model was wrong.
$2.6B
Average cost to bring a drug to market
90%
Clinical trial failure rate
~40%
Failures due to efficacy/toxicity caught too late
10–15 yrs
Average development timeline
OUR APPROACH
We Don't Just Find Good Molecules. We Map Where They Fail.
MolForge takes a fundamentally different approach. Rather than ranking molecules by predicted potency alone, we map the entire failure boundary of the chemical space around your target. Our ROBOGATE-based adaptive sampling explores thousands of structural variants, identifying exactly which modifications lead to cardiac toxicity, poor bioavailability, or insufficient potency — before any synthesis happens.
SCIENTIFIC POSITION
Built by Engineers. Designed for Drug Hunters.
MolForge is built by computational scientists and engineers, not by drug hunters. We do not claim to replace medicinal chemistry expertise. What we offer is a rigorous, reproducible, uncertainty-quantified computational layer — enabling experienced discovery teams to prioritize experiments and avoid predictable failures.
REGULATORY CONTEXT
Regulatory Context
Per FDA's January 2025 draft guidance on Artificial Intelligence in Drug Discovery, MolForge's outputs are classified as early discovery informational tools — explicitly excluded from high-risk AI device classification. All predictions are provided for informational purposes only and require expert scientific interpretation before any experimental or clinical decision.
PROGRESS
Building in Public. Validated in Private.
We believe in transparency about our methods and progress — within the bounds of responsible IP protection.
March 2026
TYK2 PoC complete. QSAR benchmark R=0.562. Phase 1.25 PASS (95% synthesizable).
March 2026
Top 5 compounds achieved Tier 2 (Structure Verified, ligand_ptm avg 0.883).
March 2026
24/7 automated pipeline launched. Failure boundary heatmap operational.
Q2 2026
External CRO assay (Gate B). Target: ≥40% hit rate.
Q2 2026
Provisional patent filing. ROBOGATE failure boundary mapping method.
Q3 2026
First NDA-based pilot with biotech partner (Gate A+B).
Q4 2026
Full licensing program launch (Gate A+B+C).
CONTACT
Partner With Us
We're currently accepting NDA-based evaluation partnerships with Series A–B biotechs and pharma R&D teams working on autoimmune, oncology, or fibrosis targets.
contact@molforgeai.com